1092804-88-0

1092804-88-0 structure

Name: Ranolazine-d8
Chemical Name: Ranolazine-d8
CAS Number: 1092804-88-0
Molecular Formula: C₂₄H₂₅D₈N₃O₄
Molecular Weight: 435.59
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Calcium Channel
Create Date: 2021-10-08 10:55:18
Modify Date: 2024-07-03 18:33:27
Ranolazine-d8 (CVT 303-d8) is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

Name	Ranolazine-d8

Description	Ranolazine-d8 (CVT 303-d8) is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel Research Areas >> Cancer Research Areas >> Cardiovascular Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73. [3]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. [4]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

Molecular Formula	C₂₄H₂₅D₈N₃O₄
Molecular Weight	435.59

1092804-88-0	1246816-00-1
122312-55-4	1092804-87-9
95635-55-5	95635-56-6
1054624-77-9	110445-25-5
35434-71-0	2037-26-5